United States Vaccines Market Valuation To Cross USD 30 Billion By 2027

June 17, 2022


As per the research report titled ‘United States Vaccines Market Size, Top 45 Vaccines Brand In-depth Analysis, Trends, Shares, Insights, and Forecasts to 2027’, available with MarketStudyReport, the United States vaccines market is projected to accrue a valuation of USD 30 Billion by 2027.


Increased demand for vaccines due to the outbreak of COVID-19, focus on finding the most affordable way of treating infections & reducing casualties, rising prevalence of disorders & infections, and high vulnerability towards diseases among aging population and children are propelling the growth of the United States vaccines market.


Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3950418/  


Furthermore, increased awareness regarding immunization among individuals, supportive government initiatives, as well as increased investments and collaborations by organizations for ramping up the manufacturing and supply are helping the market to grow.


Along with the in-depth evaluation of the emerging industry trends and prime growth factors, the report also covers the constraints and difficulties prevailing in the business sphere, combined with the proposed solutions to facilitate entrepreneurs in boosting their revenue flow.


The research report forecasts the growth pattern of the United States vaccine marketplace over 2021-2027, looking at the historical facts from 2018 to 2020, combining crucial elements such as growth trends, key insights, and pricing information for better understanding.


A detailed analysis of the market's size in terms of value, as well as the share held by top 45 vaccines brands used in the U.S. is entailed in the business intelligence report. It delves into insights and pricing trends for these 45 vaccinations, including Afluria Quadrivalent, Havrix/Twinrix/Engerix-B, TDVAX, Pediarix/Infanrix, Rotateq, Pentacel, Trumenba, Bexsero, Adacel, Fluarix/FluLaval, Proquad, Varivax, Flublok, Gardasil 9, Imovax, MenQuadfi, ActHIB, Recombivax HB, Twinrix, Vaqta, Vaxelis, Kinrix, Daptacel, Quadracel, Pentacel, IPOL, Havrix, Engerix B, PedvaxHIB, Hiberix, Tenivac, Prevnar 13, Fluzone, Fluad, Menactra, Pneumovax 23, M-M-R II, Boostrix, Menveo, Shingrix, Rotarix, Heplisav-B, FluMist Quadrivalent, and Flucelvax Quadrivalent.


Lastly, details about the overall valuation generated by the prominent players, their present product portfolios, promising vaccines, and the latest developments are enlisted to figure out the competitive panorama. The well-known organizations expected to remain afloat in the United States vaccines market are Dynavax Technologies Corporation, AstraZeneca plc, Sanofi Pasteur, Merck & Co. Inc., Pfizer Inc., Grifols S.A., Seqirus (CSL Limited), and GlaxoSmithKline plc (GSK).

Chat with us